Allovir Historical Balance Sheet
ALVR Stock | USD 0.45 0.01 2.17% |
Trend analysis of Allovir balance sheet accounts such as Other Current Liab of 41.8 K, Total Current Liabilities of 21.2 M or Total Stockholder Equity of 158.9 M provides information on Allovir's total assets, liabilities, and equity, which is the actual value of Allovir to its prevalent stockholders. By breaking down trends over time using Allovir balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Allovir latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Allovir is a good buy for the upcoming year.
Allovir Inventory |
|
Allovir |
About Allovir Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Allovir at a specified time, usually calculated after every quarter, six months, or one year. Allovir Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Allovir and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Allovir currently owns. An asset can also be divided into two categories, current and non-current.
Allovir Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Allovir assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Allovir books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Allovir balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Allovir are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Accounts Payable
An accounting item on the balance sheet that represents Allovir obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Allovir are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most accounts from Allovir's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Allovir current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allovir. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Allovir Stock, please use our How to Invest in Allovir guide.At this time, Allovir's Other Current Assets are relatively stable compared to the past year. As of 12/15/2024, Total Liabilities is likely to grow to about 56.5 M, while Total Current Liabilities is likely to drop slightly above 21.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 15.3M | 6.9M | 44K | 41.8K | Total Assets | 286.6M | 277.1M | 190.8M | 236.5M |
Allovir balance sheet Correlations
Click cells to compare fundamentals
Allovir Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Allovir balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 139.4M | 370.8M | 286.6M | 277.1M | 190.8M | 236.5M | |
Other Current Liab | 5.4M | 4.9M | 15.3M | 6.9M | 44K | 41.8K | |
Total Current Liabilities | 9.1M | 12.3M | 37.9M | 24.3M | 28.4M | 21.2M | |
Total Stockholder Equity | (51.5M) | 353.1M | 225.3M | 224.5M | 145.8M | 158.9M | |
Net Tangible Assets | (51.5M) | 353.1M | 225.3M | 224.5M | 258.2M | 158.6M | |
Net Debt | (49.3M) | (114.0M) | (171.6M) | (70.7M) | (62.7M) | (65.8M) | |
Retained Earnings | (55.3M) | (125.1M) | (297.1M) | (465.8M) | (656.2M) | (623.4M) | |
Accounts Payable | 630K | 963K | 8.4M | 3.0M | 6.8M | 3.6M | |
Cash | 61.1M | 122.7M | 201.7M | 106.1M | 90.1M | 110.7M | |
Non Current Assets Total | 12.1M | 9.5M | 33.2M | 34.0M | 3.2M | 3.0M | |
Cash And Short Term Investments | 126.1M | 356.3M | 248.1M | 233.8M | 183.9M | 214.6M | |
Net Receivables | 560K | 450K | 50K | 157K | 206K | 230K | |
Common Stock Shares Outstanding | 65.1M | 26.9M | 62.8M | 76.7M | 104.1M | 68.3M | |
Short Term Investments | 65.0M | 233.7M | 46.5M | 127.7M | 93.8M | 103.9M | |
Liabilities And Stockholders Equity | 139.4M | 370.8M | 286.6M | 277.1M | 190.8M | 236.5M | |
Non Current Liabilities Total | 181.8M | 5.5M | 23.5M | 28.2M | 16.6M | 15.8M | |
Capital Lease Obligations | 11.8M | 8.7M | 30.1M | 35.4M | 27.4M | 20.8M | |
Other Current Assets | 676K | 9.5M | 5.2M | 9.1M | 3.5M | 5.1M | |
Other Stockholder Equity | (169.4M) | 478.3M | 522.5M | 690.8M | 802.0M | 416.7M | |
Total Liab | 190.9M | 17.8M | 61.3M | 52.6M | 45.0M | 56.5M | |
Net Invested Capital | (51.5M) | 353.1M | 225.3M | 224.5M | 145.8M | 158.9M | |
Total Current Assets | 127.3M | 361.3M | 253.3M | 243.1M | 187.6M | 219.6M | |
Net Working Capital | 118.2M | 349.0M | 215.5M | 218.7M | 159.3M | 198.4M |
Pair Trading with Allovir
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.Moving together with Allovir Stock
Moving against Allovir Stock
0.78 | DYAI | Dyadic International | PairCorr |
0.67 | ESPR | Esperion Therapeutics | PairCorr |
0.63 | BMY | Bristol Myers Squibb | PairCorr |
0.45 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
0.36 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.